Moleculin Biotech, Inc.: management transactions · United States · SEC (Form 4)

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq market in the United States and focused on the clinical development of therapies for hard-to-treat cancers and, to a more limited extent, viral diseases. Headquartered in Houston, Texas, the company was formed in July 2015 and has since remained a research-driven biotech with a portfolio built around proprietary drug candidates rather than marketed products. As a result, Moleculin should be viewed as a clinical-stage company whose valuation is highly dependent on trial outcomes, regulatory progress, and access to external capital. The company’s lead asset is Annamycin, a next-generation anthracycline designed to address multidrug resistance mechanisms and avoid the cardiotoxicity associated with many traditional anthracyclines. Moleculin is developing Annamycin primarily for relapsed or refractory acute myeloid leukemia (R/R AML) and for soft tissue sarcoma lung metastases. The lead AML program is MIRACLE, a pivotal adaptive Phase 2B/3 study evaluating Annamycin in combination with cytarabine. Moleculin also develops WP1066, an immune/transcription modulator that targets STAT3 and related oncogenic pathways, with ongoing or planned research in brain tumors, pancreatic cancer, and other oncology settings. A third program, WP1122, is being explored for potential antiviral applications and selected oncology indications. From a competitive standpoint, Moleculin operates in a highly contested small-cap biotech segment dominated by better-capitalized peers with broader pipelines and stronger funding flexibility. Its differentiators are scientific specificity, a focus on high-unmet-need cancer indications, and the possibility of significant upside if one of its lead programs succeeds clinically or advances toward approval. The trade-off is substantial execution risk and ongoing financing dependence; the company has repeatedly indicated that additional capital will be required to support its clinical development plans. Recent developments have been clinically meaningful. In 2025 and early 2026, Moleculin reported continued progress in the MIRACLE trial, including completion of treatment for the 45 patients required for the first planned interim unblinding and geographic expansion of enrollment across multiple countries. The company also released positive topline data for Annamycin in soft tissue sarcoma lung metastases and positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors. For French, Belgian, and Swiss investors, Moleculin remains a speculative Nasdaq-listed healthcare name in the United States: potentially high reward, but with elevated clinical, regulatory, and financing risk.